Overview

A Study of Single and Multiple Oral Doses of TollB-001

Status:
Recruiting
Trial end date:
2024-06-09
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and tolerability of TollB-001 following the administration of single or multiple oral doses in healthy adult subjects
Phase:
Phase 1
Details
Lead Sponsor:
Toll Biotech Co. Ltd. (Beijing)